Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARROWHEAD PHARMACEUTICALS, INC. Director's Dealing 2016

Jan 5, 2016

31071_dirs_2016-01-04_ee721058-0253-40a5-aefb-9d9ba73eb424.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2016-01-01

Reporting Person: Leone Peter Brian (VP, Strategy & Program Mgmt)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-01-01 Stock Options $6.15 A 50000 Acquired 2026-01-01 Common Stock (50000) Direct

Footnotes

F1: Option vests and becomes exercisable over a four year period from date of grant.